Key result
Biowire II platform replicates fibrotic myocardium to establish a preclinical compound screening system.
Why the study?
The discovery of efficient antifibrotic compounds for myocardial fibrosis has been hampered by the lack of a physiologically relevant disease model.
Population
Biowire II platform engineered human cardiac tissues
Design
In vitro preclinical model development and compound screening system
Authors
Loading...
New fibrosis model enables compound screening; leaves open clinical translation pending human validation.
The Biowire II platform provides a high-fidelity in vitro model of human myocardial fibrosis that can facilitate preclinical screening of antifibrotic compounds.
Wang et al. (2019) studied Myocardial fibrosis. Biowire II platform (in vitro model) was evaluated on Development of a disease model of human myocardial fibrosis and compound screening system. The Biowire II platform successfully recapitulates contractile, biomechanical, and electrophysiological complexities of fibrotic myocardium to establish a preclinical compound screening system.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: